≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Toxoplasmosis, including avohilmo

Endpoint Browser PheWeb

AB1_TOXOPLASMOSIS_WIDE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Primary healthcare outpatient: ICD-10 — B58
  • Hospital discharge: ICD-10 — B58
  • Hospital discharge: ICD-9 — 130
  • Hospital discharge: ICD-8 — 130
  • Cause of death: ICD-10 — B58
  • Cause of death: ICD-9 — 130
  • Cause of death: ICD-8 — 130

3 out of 7 registries used, show all original rules.

215

4. Check minimum number of events

None

215

5. Include endpoints

None

215

6. Filter based on genotype QC (FinnGen only)

211

Control definitions (FinnGen only)

Control exclude
AB1_PROTOZOAL

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF5

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 211 137 74
Unadjusted period prevalence (%) 0.04 0.05 0.03
Median age at first event (years) 33.74 32.48 36.06

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
215
Matched controls
2150
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H32.0*B58.0
ICD-10 Finland
Toxoplasma chorioretinitis
+∞
75.6
68
*
B58.9
ICD-10 Finland
Toxoplasmosis, unspecified
+∞
33.2
31
*
B58.0
ICD-10 Finland
Toxoplasma oculopathy
+∞
33.2
31
*
13000
ICD-8 Finland
Toxoplasmosis, Acquired
+∞
29.9
28
*
13099
ICD-8 Finland
Toxoplasmosis, Unspecified
+∞
19.0
18
*
1302A
ICD-9 Finland
Toxoplasmosis, Chorioretinitis due to toxoplasmosis
+∞
19.0
18
*
H32.0
ICD-10 Finland
Chorioretinal inflammation in infectious and parasitic diseases classified elsewhere
+∞
18.0
17
*
H20.0
ICD-10 Finland
Acute and subacute iridocyclitis
6.5
13.4
23
39
H30.0
ICD-10 Finland
Focal chorioretinal inflammation
+∞
12.6
12
*
S01CA02
ATC
prednisolone and antiinfectives; ophthalmic
21.5
11.3
16
8
1309X
ICD-9 Finland
Toxoplasmosis, unspecified
+∞
10.5
10
*
H30.9
ICD-10 Finland
Chorioretinal inflammation, unspecified
104.4
9.5
10
*
H02AB07
ATC
prednisone; oral
3.1
9.5
45
168
S01BA04
ATC
prednisolone; ophthalmic
9.7
9.2
18
20
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.8
9.2
56
240
XCK10
NOMESCO Finland
Photography of fundus of eye
3.4
8.6
33
108
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
4.6
8.1
20
47
J01FF01
ATC
clindamycin; systemic
2.4
7.8
75
398
H30.2
ICD-10 Finland
Posterior cyclitis
82.8
7.5
8
*
36504
ICD-8 Finland
Choroiditis, Retinis, Retino-chorioiditis
+∞
7.3
7
*
13020
ICD-8 Finland
Toxoplasmosis, Late effects of intra-utrine infection
+∞
7.3
7
*

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Ophthalmology
18 [38004463]
8.4e-01
1.3e+00
3.4e+00
1.0e+50
4.1e+00
2.7e+00
1.5e+00
cases:19.05%
controls:9.22%
cases:14.29%
controls:4.37%
cases:18.37%
controls:0.76%
cases:57.82%
controls:0.00%
cases:34.69%
controls:0.90%
cases:42.76%
controls:4.86%
cases:37.31%
controls:11.98%
28
133
119
1309
21
63
126
1379
27
11
120
1431
85
0
62
1442
51
13
96
1429
62
69
83
1350
50
160
84
1176
Emergency Room Visit
ER [9203]
2.8e-01
1.1e+00
2.8e+00
—
2.1e+00
9.1e-01
6.1e-01
cases:29.93%
controls:24.34%
cases:25.17%
controls:9.99%
cases:17.01%
controls:1.18%
—
—
cases:9.52%
controls:1.32%
cases:21.38%
controls:9.87%
cases:35.82%
controls:23.20%
44
351
103
1091
37
144
110
1298
25
17
122
1425
—
14
19
133
1423
31
140
114
1279
48
310
86
1026
Internal Medicine
11 [38004456]
2.6e-01
1.0e+00
2.5e+00
1.0e+50
2.2e+00
1.0e+00
4.5e-01
cases:19.73%
controls:15.88%
cases:16.33%
controls:6.66%
cases:10.20%
controls:0.90%
cases:13.61%
controls:0.00%
cases:8.16%
controls:0.97%
cases:15.86%
controls:6.27%
cases:23.88%
controls:16.69%
29
229
118
1213
24
96
123
1346
15
13
132
1429
20
0
127
1442
12
14
135
1428
23
89
122
1330
32
223
102
1113
prednisolone
A07EA01 [21600653]
-2.0e-01
6.8e-01
2.3e+00
—
2.8e+00
1.5e+00
1.6e-01
cases:4.76%
controls:5.76%
cases:5.44%
controls:2.84%
cases:5.44%
controls:0.55%
—
—
cases:8.16%
controls:0.55%
cases:10.34%
controls:2.54%
cases:7.46%
controls:6.44%
7
83
140
1359
8
41
139
1401
8
8
139
1434
—
12
8
135
1434
15
36
130
1383
10
86
124
1250
prednisolone; oral, parenteral
H02AB06 [21602734]
-2.0e-01
6.8e-01
2.3e+00
—
2.8e+00
1.5e+00
1.6e-01
cases:4.76%
controls:5.76%
cases:5.44%
controls:2.84%
cases:5.44%
controls:0.55%
—
—
cases:8.16%
controls:0.55%
cases:10.34%
controls:2.54%
cases:7.46%
controls:6.44%
7
83
140
1359
8
41
139
1401
8
8
139
1434
—
12
8
135
1434
15
36
130
1383
10
86
124
1250
Outpatient Visit
OP [9202]
2.2e-01
7.0e-01
1.5e+00
—
2.4e+00
1.3e+00
5.9e-01
cases:56.46%
controls:51.11%
cases:51.70%
controls:34.60%
cases:29.25%
controls:8.39%
—
—
cases:47.62%
controls:7.56%
cases:65.52%
controls:34.11%
cases:73.88%
controls:61.15%
83
737
64
705
76
499
71
943
43
121
104
1321
—
70
109
77
1333
95
484
50
935
99
817
35
519
Eosinophils [#/volume] in Blood
26449-9 [3013115]
7.4e-01
1.0e+00
1.9e+00
—
2.9e+00
1.1e+00
-1.1e-01
cases:9.52%
controls:4.79%
cases:8.16%
controls:3.12%
cases:4.76%
controls:0.76%
—
—
cases:6.12%
controls:0.35%
cases:9.66%
controls:3.52%
cases:6.72%
controls:7.41%
14
69
133
1373
12
45
135
1397
7
11
140
1431
—
9
5
138
1437
14
50
131
1369
9
99
125
1237
Outpatient Hospital
22 [8756]
2.3e-01
8.3e-01
2.2e+00
1.0e+50
2.2e+00
8.0e-01
7.0e-01
cases:23.13%
controls:19.28%
cases:11.56%
controls:5.41%
cases:4.76%
controls:0.55%
cases:3.40%
controls:0.00%
cases:5.44%
controls:0.62%
cases:13.10%
controls:6.34%
cases:28.36%
controls:16.39%
34
278
113
1164
17
78
130
1364
7
8
140
1434
5
0
142
1442
8
9
139
1433
19
90
126
1329
38
219
96
1117
Infectious Disease
44 [38004484]
—
2.0e+00
—
1.0e+50
—
2.8e+00
1.2e+00
—
—
cases:4.08%
controls:0.55%
—
—
cases:8.16%
controls:0.00%
—
—
cases:11.03%
controls:0.78%
cases:5.22%
controls:1.57%
—
6
8
141
1434
—
12
0
135
1442
—
16
11
129
1408
7
21
127
1315
Inpatient Hospital
21 [8717]
1.7e-01
5.9e-01
1.7e+00
1.0e+50
1.7e+00
8.3e-01
4.4e-01
cases:30.61%
controls:27.18%
cases:17.69%
controls:10.68%
cases:7.48%
controls:1.39%
cases:11.56%
controls:0.00%
cases:6.12%
controls:1.18%
cases:20.00%
controls:9.87%
cases:33.58%
controls:24.48%
45
392
102
1050
26
154
121
1288
11
20
136
1422
17
0
130
1442
9
17
138
1425
29
140
116
1279
45
327
89
1009
clindamycin; oral, parenteral
J01FF01 [21602985]
1.2e+00
—
1.0e+50
1.0e+50
—
2.3e+00
1.6e+00
cases:6.12%
controls:2.01%
—
—
cases:7.48%
controls:0.00%
cases:8.84%
controls:0.00%
—
—
cases:7.59%
controls:0.85%
cases:10.45%
controls:2.40%
9
29
138
1413
—
11
0
136
1442
13
0
134
1442
—
11
12
134
1407
14
32
120
1304
Examination of eyes and vision
Z01.0 [45566391]
1.4e+00
—
—
—
—
2.3e+00
9.2e-01
cases:8.16%
controls:2.08%
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.42%
cases:5.97%
controls:2.47%
12
30
135
1412
—
—
—
—
6
6
139
1413
8
33
126
1303
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
7.0e-01
8.2e-01
1.5e+00
—
2.5e+00
1.1e+00
1.9e-02
cases:8.84%
controls:4.58%
cases:6.80%
controls:3.12%
cases:3.40%
controls:0.76%
—
—
cases:4.08%
controls:0.35%
cases:9.66%
controls:3.31%
cases:7.46%
controls:7.34%
13
66
134
1376
10
45
137
1397
5
11
142
1431
—
6
5
141
1437
14
47
131
1372
10
98
124
1238
Pharmacy visit
OMOP4822462 [581458]
-7.2e-02
2.1e-01
6.9e-01
2.1e+00
7.5e-01
2.2e-01
7.5e-02
cases:77.55%
controls:78.78%
cases:70.75%
controls:66.16%
cases:47.62%
controls:31.35%
cases:14.97%
controls:2.01%
cases:49.66%
controls:31.76%
cases:73.79%
controls:69.27%
cases:85.82%
controls:84.88%
114
1136
33
306
104
954
43
488
70
452
77
990
22
29
125
1413
73
458
74
984
107
983
38
436
115
1134
19
202
Differential panel, method unspecified - Blood
69738-3 [42870588]
7.8e-01
9.3e-01
2.2e+00
—
—
1.4e+00
3.2e-01
cases:6.12%
controls:2.91%
cases:4.76%
controls:1.94%
cases:4.08%
controls:0.49%
—
—
—
—
cases:7.59%
controls:1.97%
cases:5.97%
controls:4.42%
9
42
138
1400
7
28
140
1414
6
7
141
1435
—
—
11
28
134
1391
8
59
126
1277
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1.8e-01
2.7e-01
1.5e+00
—
1.7e+00
5.0e-01
-6.6e-02
cases:15.65%
controls:13.38%
cases:12.24%
controls:9.64%
cases:9.52%
controls:2.29%
—
—
cases:7.48%
controls:1.46%
cases:15.86%
controls:10.29%
cases:18.66%
controls:19.69%
23
193
124
1249
18
139
129
1303
14
33
133
1409
—
11
21
136
1421
23
146
122
1273
25
263
109
1073
Case Management Agency
251B00000X [38004193]
-3.4e-02
5.6e-02
7.7e-01
2.4e+00
5.8e-01
2.0e-01
1.2e-01
cases:36.73%
controls:37.52%
cases:31.29%
controls:30.10%
cases:21.77%
controls:11.37%
cases:11.56%
controls:1.18%
cases:17.01%
controls:10.26%
cases:35.86%
controls:31.36%
cases:51.49%
controls:48.58%
54
541
93
901
46
434
101
1008
32
164
115
1278
17
17
130
1425
25
148
122
1294
52
445
93
974
69
649
65
687
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
1.8e-01
6.2e-01
1.9e+00
—
—
1.0e+00
-3.8e-02
cases:10.20%
controls:8.67%
cases:7.48%
controls:4.16%
cases:5.44%
controls:0.83%
—
—
—
—
cases:11.03%
controls:4.30%
cases:11.94%
controls:12.35%
15
125
132
1317
11
60
136
1382
8
12
139
1430
—
—
16
61
129
1358
16
165
118
1171
Basophils [#/volume] in Blood
26444-0 [3006315]
7.5e-01
9.1e-01
1.5e+00
—
2.5e+00
1.1e+00
-5.0e-02
cases:8.84%
controls:4.37%
cases:6.80%
controls:2.84%
cases:3.40%
controls:0.76%
—
—
cases:4.08%
controls:0.35%
cases:8.97%
controls:3.31%
cases:6.72%
controls:7.04%
13
63
134
1379
10
41
137
1401
5
11
142
1431
—
6
5
141
1437
13
47
132
1372
9
94
125
1242
Monocytes [#/volume] in Blood
26484-6 [3001604]
7.7e-01
9.4e-01
1.5e+00
—
2.5e+00
1.1e+00
-5.0e-02
cases:8.84%
controls:4.30%
cases:6.80%
controls:2.77%
cases:3.40%
controls:0.76%
—
—
cases:4.08%
controls:0.35%
cases:8.97%
controls:3.24%
cases:6.72%
controls:7.04%
13
62
134
1380
10
40
137
1402
5
11
142
1431
—
6
5
141
1437
13
46
132
1373
9
94
125
1242
prednisolone
S03BA02 [21605202]
—
—
—
—
1.0e+50
—
2.5e+00
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.00%
—
—
cases:8.21%
controls:0.75%
—
—
—
—
7
0
140
1442
—
11
10
123
1326
prednisolone
S01BA04 [21603621]
—
—
—
—
1.0e+50
—
2.5e+00
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.00%
—
—
cases:8.21%
controls:0.75%
—
—
—
—
7
0
140
1442
—
11
10
123
1326
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
-1.4e-02
1.2e-01
1.1e+00
—
1.3e+00
2.4e-01
-2.4e-01
cases:17.69%
controls:17.89%
cases:18.37%
controls:16.64%
cases:10.20%
controls:3.81%
—
—
cases:10.88%
controls:3.19%
cases:21.38%
controls:17.62%
cases:23.13%
controls:27.77%
26
258
121
1184
27
240
120
1202
15
55
132
1387
—
16
46
131
1396
31
250
114
1169
31
371
103
965
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
-1.4e-02
1.2e-01
1.0e+00
—
1.3e+00
2.4e-01
-2.4e-01
cases:17.69%
controls:17.89%
cases:18.37%
controls:16.64%
cases:10.20%
controls:3.88%
—
—
cases:10.88%
controls:3.19%
cases:21.38%
controls:17.69%
cases:23.13%
controls:27.77%
26
258
121
1184
27
240
120
1202
15
56
132
1386
—
16
46
131
1396
31
251
114
1168
31
371
103
965
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
-1.4e-02
1.1e-01
1.0e+00
—
1.3e+00
2.3e-01
-2.5e-01
cases:17.69%
controls:17.89%
cases:18.37%
controls:16.71%
cases:10.20%
controls:3.88%
—
—
cases:10.88%
controls:3.19%
cases:21.38%
controls:17.76%
cases:23.13%
controls:27.92%
26
258
121
1184
27
241
120
1201
15
56
132
1386
—
16
46
131
1396
31
252
114
1167
31
373
103
963
MCH [Entitic mass]
28539-5 [3035941]
-1.4e-02
1.2e-01
1.0e+00
—
1.3e+00
2.4e-01
-2.4e-01
cases:17.69%
controls:17.89%
cases:18.37%
controls:16.64%
cases:10.20%
controls:3.88%
—
—
cases:10.88%
controls:3.19%
cases:21.38%
controls:17.69%
cases:23.13%
controls:27.77%
26
258
121
1184
27
240
120
1202
15
56
132
1386
—
16
46
131
1396
31
251
114
1168
31
371
103
965
Platelets [#/volume] in Blood
26515-7 [3007461]
2.3e-04
1.2e-01
1.0e+00
—
1.3e+00
2.4e-01
-2.4e-01
cases:17.69%
controls:17.68%
cases:18.37%
controls:16.57%
cases:10.20%
controls:3.88%
—
—
cases:10.88%
controls:3.19%
cases:21.38%
controls:17.62%
cases:23.13%
controls:27.77%
26
255
121
1187
27
239
120
1203
15
56
132
1386
—
16
46
131
1396
31
250
114
1169
31
371
103
965
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
-1.4e-02
1.2e-01
1.0e+00
—
1.3e+00
2.4e-01
-2.4e-01
cases:17.69%
controls:17.89%
cases:18.37%
controls:16.64%
cases:10.20%
controls:3.88%
—
—
cases:10.88%
controls:3.19%
cases:21.38%
controls:17.69%
cases:23.13%
controls:27.77%
26
258
121
1184
27
240
120
1202
15
56
132
1386
—
16
46
131
1396
31
251
114
1168
31
371
103
965
sulfadiazine and trimethoprim
J01EE02 [21602962]
8.7e-01
—
—
1.0e+50
1.0e+50
2.3e+00
7.8e-01
cases:5.44%
controls:2.36%
—
—
—
—
cases:6.80%
controls:0.00%
cases:7.48%
controls:0.00%
cases:6.90%
controls:0.70%
cases:4.48%
controls:2.10%
8
34
139
1408
—
—
10
0
137
1442
11
0
136
1442
10
10
135
1409
6
28
128
1308
azithromycin; oral, parenteral
J01FA10 [21602978]
4.7e-01
7.3e-01
—
—
2.3e+00
5.3e-01
1.6e-01
cases:11.56%
controls:7.56%
cases:4.08%
controls:2.01%
—
—
—
—
cases:4.08%
controls:0.42%
cases:4.14%
controls:2.47%
cases:9.70%
controls:8.38%
17
109
130
1333
6
29
141
1413
—
—
6
6
141
1436
6
35
139
1384
13
112
121
1224
esomeprazole; oral, parenteral
A02BC05 [21600100]
1.5e-01
4.1e-01
—
—
2.3e+00
3.4e-01
2.0e-01
cases:5.44%
controls:4.72%
cases:3.40%
controls:2.29%
—
—
—
—
cases:4.08%
controls:0.42%
cases:3.45%
controls:2.47%
cases:8.21%
controls:6.81%
8
68
139
1374
5
33
142
1409
—
—
6
6
141
1436
5
35
140
1384
11
91
123
1245
dexamethasone
S03BA01 [21605201]
—
—
—
—
—
2.2e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:0.56%
cases:4.48%
controls:1.27%
—
—
—
—
—
7
8
138
1411
6
17
128
1319
dexamethasone
S01BA01 [21603618]
—
—
—
—
—
2.2e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:0.56%
cases:4.48%
controls:1.27%
—
—
—
—
—
7
8
138
1411
6
17
128
1319
Other investigative procedure of eye
XCW99 [2001301491]
—
—
—
—
—
2.0e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.56%
cases:3.73%
controls:0.97%
—
—
—
—
—
6
8
139
1411
5
13
129
1323
Bacteria [Presence] in Urine
87829-8 [36304419]
—
1.1e+00
—
—
—
2.0e+00
3.4e-01
—
—
cases:3.40%
controls:1.11%
—
—
—
—
—
—
cases:4.14%
controls:0.56%
cases:3.73%
controls:2.69%
—
5
16
142
1426
—
—
—
6
8
139
1411
5
36
129
1300
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
4.6e-01
7.9e-01
1.3e+00
—
2.0e+00
9.2e-01
-2.3e-01
cases:8.84%
controls:5.76%
cases:8.84%
controls:4.23%
cases:5.44%
controls:1.53%
—
—
cases:6.12%
controls:0.90%
cases:9.66%
controls:4.09%
cases:6.72%
controls:8.31%
13
83
134
1359
13
61
134
1381
8
22
139
1420
—
9
13
138
1429
14
58
131
1361
9
111
125
1225
Supplier / Service Provider
OMOP5117446 [33004]
-1.6e+00
—
—
—
—
—
3.6e+00
cases:7.48%
controls:28.92%
—
—
—
—
—
—
—
—
—
—
cases:11.94%
controls:0.37%
11
417
136
1025
—
—
—
—
—
16
5
118
1331
Inpatient Visit
IP [9201]
3.4e-01
9.3e-01
—
1.0e+50
—
1.8e+00
7.9e-01
cases:10.88%
controls:7.98%
cases:6.12%
controls:2.50%
—
—
cases:16.33%
controls:0.00%
—
—
cases:8.97%
controls:1.55%
cases:13.43%
controls:6.59%
16
115
131
1327
9
36
138
1406
—
24
0
123
1442
—
13
22
132
1397
18
88
116
1248
Angiography of heart and/or coronary arteries
FN1AC [2001302996]
1.8e+00
—
—
—
—
—
—
cases:5.44%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
—
—
8
14
139
1428
—
—
—
—
—
—
Obstetrics / Gynecology
16 [38004461]
-3.6e-01
-6.3e-02
—
1.0e+50
1.5e+00
3.5e-01
4.1e-01
cases:12.93%
controls:17.61%
cases:6.80%
controls:7.21%
—
—
cases:4.08%
controls:0.00%
cases:6.12%
controls:1.39%
cases:8.28%
controls:5.99%
cases:22.39%
controls:16.02%
19
254
128
1188
10
104
137
1338
—
6
0
141
1442
9
20
138
1422
12
85
133
1334
30
214
104
1122
Neurology
13 [38004458]
4.4e-01
1.5e+00
—
—
—
9.0e-01
5.0e-01
cases:10.20%
controls:6.80%
cases:9.52%
controls:2.36%
—
—
—
—
—
—
cases:6.21%
controls:2.61%
cases:12.69%
controls:8.08%
15
98
132
1344
14
34
133
1408
—
—
—
9
37
136
1382
17
108
117
1228
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
-1.8e-01
-1.0e-01
1.3e+00
—
1.4e+00
2.9e-01
-1.5e-01
cases:12.24%
controls:14.36%
cases:10.88%
controls:11.93%
cases:7.48%
controls:2.15%
—
—
cases:7.48%
controls:1.94%
cases:15.17%
controls:11.84%
cases:19.40%
controls:21.93%
18
207
129
1235
16
172
131
1270
11
31
136
1411
—
11
28
136
1414
22
168
123
1251
26
293
108
1043
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
-1.3e-01
-1.1e-01
1.3e+00
—
1.4e+00
3.1e-01
-1.2e-01
cases:12.93%
controls:14.42%
cases:10.88%
controls:12.00%
cases:7.48%
controls:2.15%
—
—
cases:7.48%
controls:1.94%
cases:15.86%
controls:12.12%
cases:20.15%
controls:22.16%
19
208
128
1234
16
173
131
1269
11
31
136
1411
—
11
28
136
1414
23
172
122
1247
27
296
107
1040
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
6.8e-02
1.0e-01
8.5e-01
—
1.4e+00
7.8e-02
-2.5e-01
cases:11.56%
controls:10.89%
cases:10.20%
controls:9.29%
cases:6.12%
controls:2.70%
—
—
cases:7.48%
controls:2.01%
cases:11.03%
controls:10.29%
cases:14.93%
controls:18.41%
17
157
130
1285
15
134
132
1308
9
39
138
1403
—
11
29
136
1413
16
146
129
1273
20
246
114
1090
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
-2.3e-01
2.5e-02
1.2e+00
—
1.4e+00
4.4e-01
-1.9e-01
cases:12.93%
controls:15.74%
cases:13.61%
controls:13.31%
cases:8.16%
controls:2.57%
—
—
cases:7.48%
controls:2.01%
cases:20.00%
controls:13.81%
cases:20.90%
controls:24.25%
19
227
128
1215
20
192
127
1250
12
37
135
1405
—
11
29
136
1413
29
196
116
1223
28
324
106
1012
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-1.2e-01
-2.3e-01
1.1e+00
—
1.4e+00
5.9e-02
-4.8e-01
cases:12.24%
controls:13.59%
cases:10.20%
controls:12.55%
cases:8.16%
controls:2.77%
—
—
cases:8.84%
controls:2.43%
cases:13.79%
controls:13.11%
cases:14.93%
controls:22.16%
18
196
129
1246
15
181
132
1261
12
40
135
1402
—
13
35
134
1407
20
186
125
1233
20
296
114
1040
Otolaryngology
4 [38004449]
5.3e-01
1.1e+00
—
1.0e+50
—
1.3e+00
6.2e-01
cases:10.88%
controls:6.73%
cases:7.48%
controls:2.70%
—
—
cases:3.40%
controls:0.00%
—
—
cases:7.59%
controls:2.11%
cases:11.94%
controls:6.81%
16
97
131
1345
11
39
136
1403
—
5
0
142
1442
—
11
30
134
1389
16
91
118
1245
Scheduled procedure
ZXD10 [2001311387]
7.9e-01
—
—
—
—
8.7e-01
1.3e+00
cases:7.48%
controls:3.54%
—
—
—
—
—
—
—
—
cases:3.45%
controls:1.48%
cases:10.45%
controls:2.99%
11
51
136
1391
—
—
—
—
5
21
140
1398
14
40
120
1296
Leukocytes [#/volume] in Blood
26464-8 [3010813]
-2.3e-02
1.1e-01
1.0e+00
—
1.3e+00
2.4e-01
-2.5e-01
cases:17.69%
controls:18.03%
cases:18.37%
controls:16.71%
cases:10.20%
controls:3.95%
—
—
cases:10.88%
controls:3.19%
cases:21.38%
controls:17.69%
cases:23.13%
controls:27.84%
26
260
121
1182
27
241
120
1201
15
57
132
1385
—
16
46
131
1396
31
251
114
1168
31
372
103
964
Monocytes/Leukocytes in Blood
26485-3 [3019069]
7.0e-01
8.6e-01
1.7e+00
—
—
1.2e+00
-5.5e-02
cases:8.84%
controls:4.58%
cases:6.80%
controls:2.98%
cases:3.40%
controls:0.62%
—
—
—
—
cases:9.66%
controls:3.17%
cases:5.97%
controls:6.29%
13
66
134
1376
10
43
137
1399
5
9
142
1433
—
—
14
45
131
1374
8
84
126
1252
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
7.2e-01
8.4e-01
1.7e+00
—
—
1.2e+00
-4.2e-02
cases:8.84%
controls:4.51%
cases:6.80%
controls:3.05%
cases:3.40%
controls:0.62%
—
—
—
—
cases:9.66%
controls:3.17%
cases:5.97%
controls:6.21%
13
65
134
1377
10
44
137
1398
5
9
142
1433
—
—
14
45
131
1374
8
83
126
1253
Basophils/Leukocytes in Blood
30180-4 [3022096]
7.2e-01
7.3e-01
1.7e+00
—
—
1.2e+00
-4.2e-02
cases:8.84%
controls:4.51%
cases:6.12%
controls:3.05%
cases:3.40%
controls:0.62%
—
—
—
—
cases:9.66%
controls:3.17%
cases:5.97%
controls:6.21%
13
65
134
1377
9
44
138
1398
5
9
142
1433
—
—
14
45
131
1374
8
83
126
1253
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
6.3e-01
7.3e-01
—
—
—
1.1e+00
7.1e-02
cases:8.16%
controls:4.51%
cases:6.12%
controls:3.05%
—
—
—
—
—
—
cases:8.97%
controls:3.03%
cases:6.72%
controls:6.29%
12
65
135
1377
9
44
138
1398
—
—
—
13
43
132
1376
9
84
125
1252
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
6.2e-01
7.8e-01
1.7e+00
—
—
1.1e+00
5.8e-02
cases:8.16%
controls:4.58%
cases:6.12%
controls:2.91%
cases:3.40%
controls:0.62%
—
—
—
—
cases:8.97%
controls:3.03%
cases:6.72%
controls:6.36%
12
66
135
1376
9
42
138
1400
5
9
142
1433
—
—
13
43
132
1376
9
85
125
1251
ibuprofen
R02AX02 [1588667]
1.2e-01
2.9e-01
—
—
—
-7.7e-02
7.1e-01
cases:25.17%
controls:23.02%
cases:14.29%
controls:11.10%
—
—
—
—
—
—
cases:11.72%
controls:12.54%
cases:45.52%
controls:29.04%
37
332
110
1110
21
160
126
1282
—
—
—
17
178
128
1241
61
388
73
948
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
1.2e-01
2.9e-01
—
—
—
-7.7e-02
7.1e-01
cases:25.17%
controls:23.02%
cases:14.29%
controls:11.10%
—
—
—
—
—
—
cases:11.72%
controls:12.54%
cases:45.52%
controls:29.04%
37
332
110
1110
21
160
126
1282
—
—
—
17
178
128
1241
61
388
73
948
Counselling related to known health issue
SPAT1310 [2001700411]
8.9e-02
—
—
—
—
—
2.8e-01
cases:3.40%
controls:3.12%
—
—
—
—
—
—
—
—
—
—
cases:3.73%
controls:2.84%
5
45
142
1397
—
—
—
—
—
5
38
129
1298
Pure hypercholesterolaemia
E78.0 [45542771]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
0
6
147
1436
—
—
—
0
7
145
1412
—
fluocortolone
D07AC05 [21602124]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
0
8
147
1434
—
—
—
—
—
0
10
134
1326
dexamethasone
D07AB19 [21602116]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
7
145
1412
—
Gingivitis (chronic) NOS
K05.10 [2000502717]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
0
7
147
1435
—
—
—
0
7
145
1412
—
Short blood count panel - Blood
55429-5 [40758558]
6.0e-01
8.0e-01
—
—
—
1.2e+00
—
cases:4.08%
controls:2.29%
cases:4.08%
controls:1.87%
—
—
—
—
—
—
cases:4.14%
controls:1.34%
—
—
6
33
141
1409
6
27
141
1415
—
—
—
6
19
139
1400
—
tizanidine; oral
M03BX02 [21604116]
-3.5e-01
3.7e-01
-1.0e+50
—
-1.0e+50
—
2.7e-02
cases:6.80%
controls:9.36%
cases:4.76%
controls:3.33%
cases:0.00%
controls:0.42%
—
—
cases:0.00%
controls:0.42%
—
—
cases:11.19%
controls:10.93%
10
135
137
1307
7
48
140
1394
0
6
147
1436
—
0
6
147
1436
—
15
146
119
1190
tretinoin; ointment
D10AD01 [21602293]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1436
—
—
—
—
—
—
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
Physiotherapy
R4110 [2001310233]
—
—
—
—
—
—
9.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.97%
controls:2.32%
—
—
—
—
—
—
8
31
126
1305
Schizophrenia
F20 [45542835]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
amoxicillin; oral, parenteral
J01CA04 [21602823]
1.3e-01
-7.2e-02
—
—
—
1.3e-02
3.7e-01
cases:19.05%
controls:17.06%
cases:5.44%
controls:5.83%
—
—
—
—
—
—
cases:6.21%
controls:6.13%
cases:24.63%
controls:18.49%
28
246
119
1196
8
84
139
1358
—
—
—
9
87
136
1332
33
247
101
1089
valsartan; oral
C09CA03 [21601826]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
0
8
147
1434
—
—
—
0
7
145
1412
—
General examination of pregnant woman
XMA22 [2001306916]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.42%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.97%
0
6
147
1436
0
5
147
1437
—
—
—
0
7
145
1412
0
13
134
1323
Postmenopausal bleeding
N95.0 [45567872]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
insulin degludec; parenteral
A10AE06 [43534747]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.97%
—
—
—
—
—
0
5
145
1414
0
13
134
1323
dexbrompheniramine, combinations
R06AB56 [21603469]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
0
11
134
1325
Pulmonary toxoplasmosis
J17.3*B58.3 [2000502584]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:3.40%
controls:0.00%
—
—
—
—
—
—
—
—
—
5
0
142
1442
—
—
—
Palpitations
R00.2 [45558446]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
147
1433
—
—
—
—
—
—
Flexible laryngoscopy
UDQ12 [2001301827]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1435
—
—
—
—
—
—
ranitidine bismuth citrate; oral
A02BA07 [21600088]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
0
7
147
1435
—
—
—
0
8
145
1411
—
Dislocation of patella
S83.0 [45598912]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
134
1331
Hematology
82 [38004501]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.73%
controls:0.75%
—
—
—
—
—
—
5
10
129
1326
Spinalanesthesia
WX320 [2001310799]
-1.0e+50
—
—
—
—
—
9.5e-01
cases:0.00%
controls:1.11%
—
—
—
—
—
—
—
—
—
—
cases:5.97%
controls:2.40%
0
16
147
1426
—
—
—
—
—
8
32
126
1304
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
0
17
134
1319
Recurrent depressive disorder, current episode severe without psychotic symptoms
F33.2 [45547705]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
0
8
147
1434
—
—
—
—
0
5
145
1414
—
Emergency Room and Inpatient Visit
ERIP [262]
—
1.4e+00
—
—
—
—
4.3e-02
—
—
cases:3.40%
controls:0.90%
—
—
—
—
—
—
—
—
cases:5.22%
controls:5.01%
—
5
13
142
1429
—
—
—
—
7
67
127
1269
Other medical or dental certificate
WZA90 [2001310883]
6.7e-01
—
—
—
—
—
—
cases:4.76%
controls:2.50%
—
—
—
—
—
—
—
—
—
—
—
—
7
36
140
1406
—
—
—
—
—
—
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
147
1431
—
—
—
—
—
—
Bipolar disorder Depressive episode without somatic syndrome
F31.30 [2000501976]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1436
—
—
—
—
—
—
Thorax X-ray examination
GD1AA [2001303617]
7.7e-01
—
—
—
—
—
5.0e-01
cases:6.80%
controls:3.26%
—
—
—
—
—
—
—
—
—
—
cases:6.72%
controls:4.19%
10
47
137
1395
—
—
—
—
—
9
56
125
1280
Ear symptom/complaint other
H29 [2002000484]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
10
134
1326
nimesulide; oral
M01AX17 [21604007]
—
—
—
—
—
—
9.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.73%
controls:1.42%
—
—
—
—
—
—
5
19
129
1317
Treatment-related counselling outside office
SPAT1249 [2001700350]
—
—
-1.0e+50
—
—
—
3.9e-01
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
cases:8.21%
controls:5.69%
—
—
0
9
147
1433
—
—
—
11
76
123
1260
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
—
—
—
—
—
1.3e+00
-3.1e-03
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:1.20%
cases:4.48%
controls:4.49%
—
—
—
—
—
6
17
139
1402
6
60
128
1276
formoterol and beclometasone
R03AK08 [43534839]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
134
1331
tafluprost
S01EE05 [21603714]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
6
134
1330
hepatitis B, purified antigen
J07BC01 [21601338]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
6
147
1436
—
—
—
—
—
0
5
134
1331
Gas panel - Venous blood
24339-4 [3000991]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
0
15
134
1321
Maternal care for other (suspected) fetal abnormality and damage
O35.8 [45572816]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
Secondary amenorrhoea
N91.1 [45601758]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1436
—
—
—
—
—
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
4.2e-01
5.4e-01
—
—
—
1.0e+00
-3.6e-01
cases:6.12%
controls:4.09%
cases:4.08%
controls:2.43%
—
—
—
—
—
—
cases:4.83%
controls:1.83%
cases:4.48%
controls:6.29%
9
59
138
1383
6
35
141
1407
—
—
—
7
26
138
1393
6
84
128
1252
Acute upper respiratory infection, unspecified
J06.9 [45562437]
1.8e-01
—
—
—
—
—
4.7e-01
cases:5.44%
controls:4.58%
—
—
—
—
—
—
—
—
—
—
cases:11.19%
controls:7.34%
8
66
139
1376
—
—
—
—
—
15
98
119
1238
Toxoplasmosis, unspecified
B58.9 [45585965]
—
—
—
1.0e+50
1.0e+50
1.0e+50
—
—
—
—
—
—
—
cases:19.73%
controls:0.00%
cases:8.84%
controls:0.00%
cases:8.97%
controls:0.00%
—
—
—
—
—
29
0
118
1442
13
0
134
1442
13
0
132
1419
—
Bacteria identified in Urine by Culture
630-4 [3026008]
5.6e-01
7.8e-01
—
—
—
1.1e+00
—
cases:4.76%
controls:2.77%
cases:3.40%
controls:1.60%
—
—
—
—
—
—
cases:4.14%
controls:1.41%
—
—
7
40
140
1402
5
23
142
1419
—
—
—
6
20
139
1399
—
Kolposcopy
ULA02 [2001306679]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
Monitoring the use of the aid
R5140 [2001310249]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
147
1433
—
—
—
—
—
—
Health check-up performed based on health survey in students of universities, universities of applied sciences etc.
SPAT1366 [2001700467]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1436
—
—
—
—
—
—
Pain in thoracic spine
M54.6 [45606247]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
0
5
145
1414
—
Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
11054-4 [3002109]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.62%
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
0
9
147
1433
0
6
147
1436
—
—
—
—
—
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
5.5e-01
7.8e-01
—
—
—
7.0e-01
2.4e-01
cases:7.48%
controls:4.44%
cases:5.44%
controls:2.57%
—
—
—
—
—
—
cases:4.83%
controls:2.47%
cases:8.21%
controls:6.59%
11
64
136
1378
8
37
139
1405
—
—
—
7
35
138
1384
11
88
123
1248
lidocaine
C05AD01 [21601618]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
—
—
—
—
—
1.7e+00
3.4e-01
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.78%
cases:3.73%
controls:2.69%
—
—
—
—
—
6
11
139
1408
5
36
129
1300
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
-6.1e-02
-2.2e-01
-1.0e+50
—
—
1.1e-01
-3.8e-01
cases:11.56%
controls:12.21%
cases:7.48%
controls:9.15%
cases:0.00%
controls:0.76%
—
—
—
—
cases:10.34%
controls:9.37%
cases:15.67%
controls:21.41%
17
176
130
1266
11
132
136
1310
0
11
147
1431
—
—
15
133
130
1286
21
286
113
1050
tiotropium bromide; inhalant
R03BB04 [21603296]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.90%
cases:0.00%
controls:0.62%
cases:0.00%
controls:0.49%
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.63%
cases:0.00%
controls:1.12%
0
13
147
1429
0
9
147
1433
0
7
147
1435
—
0
5
147
1437
0
9
145
1410
0
15
134
1321
Severe psychotic and other severe mental disorders
112 [2001600112]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
147
1434
—
—
—
—
—
—
dexamethasone
D10AA03 [21602286]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
7
145
1412
—
nebivolol; oral
C07AB12 [21601694]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
Periodontitis pronounced
K05.31 [2000502729]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
0
11
134
1325
brompheniramine, combinations
R06AB51 [21603466]
1.0e+00
—
—
—
—
—
—
cases:5.44%
controls:2.08%
—
—
—
—
—
—
—
—
—
—
—
—
8
30
139
1412
—
—
—
—
—
—
Other and unspecified ovarian cysts
N83.2 [45539066]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
0
6
147
1436
—
—
—
—
—
0
9
134
1327
hydroxocobalamin
V03AB33 [21605256]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
0
9
147
1433
—
—
—
—
—
0
11
134
1325
Malignant tumour
130 [2001600128]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
10
134
1326
folic acid; oral, parenteral
B03BB01 [21601129]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
0
14
134
1322
Norclozapine [Moles/volume] in Serum or Plasma
14851-0 [3008832]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.45%
—
—
—
—
—
0
5
145
1414
0
6
134
1330
Systematic individual therapy, cognitive-behavioural
IDY03 [2001304164]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
7
134
1329
Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection
24111-7 [3011371]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
0
7
147
1435
—
—
—
0
6
145
1413
—
Two-surface restoration
SFA20 [2001310359]
1.3e-01
—
-1.0e+50
—
—
—
8.2e-02
cases:8.16%
controls:7.21%
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
cases:11.19%
controls:10.40%
12
104
135
1338
—
0
6
147
1436
—
—
—
15
139
119
1197
Depressive episode, unspecified
F32.9 [45571760]
—
-1.0e+50
—
—
—
—
8.9e-01
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
cases:3.73%
controls:1.57%
—
0
9
147
1433
—
—
—
—
5
21
129
1315
hydrocortisone
C05AA01 [21601608]
5.8e-01
—
-1.0e+50
—
—
—
2.6e-01
cases:10.20%
controls:5.96%
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:7.46%
controls:5.84%
15
86
132
1356
—
0
5
147
1437
—
—
—
10
78
124
1258
Midwife
Z3232 [2001311563]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
0
5
145
1414
—
Pneumonia, unspecified
J18.9 [45601123]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
0
8
147
1434
—
—
—
—
—
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
3.3e-02
—
—
—
—
—
1.2e-02
cases:4.08%
controls:3.95%
—
—
—
—
—
—
—
—
—
—
cases:5.22%
controls:5.16%
6
57
141
1385
—
—
—
—
—
7
69
127
1267
Respiratory symptom/complaint other
R29 [2002000898]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
Preventive oral health care, extensive
SCA03 [2001310304]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
Radial styloid tenosynovitis [de Quervain]
M65.4 [45553231]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
7
134
1329
alprostadil; implant, parenteral
G04BE01 [21602646]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
134
1331
Fall on same level involving ice and snow
W00 [45756242]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
cases:0.00%
controls:0.82%
—
—
—
—
—
0
8
145
1411
0
11
134
1325
betamethasone
D07AC01 [21602120]
6.1e-01
—
—
—
-1.0e+50
-1.0e+50
—
cases:6.80%
controls:3.81%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:1.41%
—
—
10
55
137
1387
—
—
—
0
5
147
1437
0
20
145
1399
—
isosorbide mononitrate; oral
C01DA14 [21600324]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:1.73%
cases:0.00%
controls:0.35%
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
0
25
147
1417
0
5
147
1437
—
0
7
147
1435
—
—
Thrombin time
3243-3 [3036489]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
134
1331
Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
147
1434
—
—
—
—
—
—
Internal fixation of fracture of ankle using wire, rod, cerclage or pin
NHJ10 [2001308333]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
6
134
1330
Doppler ultrasound examination of heart
FM1DE [2001303299]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
7
147
1435
—
—
—
—
—
0
7
134
1329
ebastine; oral
R06AX22 [21603521]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
—
0
10
147
1432
—
—
—
—
—
Mullerian inhibiting substance [Mass/volume] in Serum or Plasma
38476-8 [3047826]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
7
134
1329
dexamethasone
C05AA09 [21601613]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
7
145
1412
—
Application of soft bandage
SPAT1211 [2001700312]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1436
—
—
—
—
—
—
Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
546-2 [3024135]
1.0e+00
—
—
—
—
-1.0e+50
4.8e-01
cases:4.76%
controls:1.80%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.27%
cases:5.22%
controls:3.29%
7
26
140
1416
—
—
—
—
0
18
145
1401
7
44
127
1292
Potassium [Moles/volume] in Arterial blood
32713-0 [3043409]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
6
134
1330
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
7
134
1329
temazepam; oral
N05CD07 [21604642]
—
—
—
—
—
1.5e+00
7.1e-01
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.78%
cases:4.48%
controls:2.25%
—
—
—
—
—
5
11
140
1408
6
30
128
1306
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
4.5e-01
1.0e+00
-1.0e+50
—
—
—
—
cases:4.08%
controls:2.64%
cases:3.40%
controls:1.25%
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
6
38
141
1404
5
18
142
1424
0
6
147
1436
—
—
—
—
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
7.4e-02
7.3e-01
—
—
-1.0e+50
4.8e-01
2.1e-01
cases:4.76%
controls:4.44%
cases:6.12%
controls:3.05%
—
—
—
—
cases:0.00%
controls:0.42%
cases:4.83%
controls:3.03%
cases:8.21%
controls:6.74%
7
64
140
1378
9
44
138
1398
—
—
0
6
147
1436
7
43
138
1376
11
90
123
1246
Nail symptom/complaint
S22 [2002000987]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
8
134
1328
Phakoemulsification with implantation of artificial lens in posterior chamber
CJE20 [2001301342]
—
-1.0e+50
—
—
—
—
1.2e+00
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
cases:5.97%
controls:1.87%
—
0
9
147
1433
—
—
—
—
8
25
126
1311
Risk factor NOS
A23 [2002000158]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1435
—
—
—
—
—
—
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
1.1e+00
—
—
—
—
—
2.3e-01
cases:4.08%
controls:1.39%
—
—
—
—
—
—
—
—
—
—
cases:3.73%
controls:2.99%
6
20
141
1422
—
—
—
—
—
5
40
129
1296
No procedures
SPAT1301 [2001700402]
—
—
—
—
—
—
2.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.48%
controls:3.44%
—
—
—
—
—
—
6
46
128
1290
formoterol and budesonide
R03AK07 [21603281]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.90%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
0
13
147
1429
0
5
147
1437
—
—
—
0
6
145
1413
—
Counselling, unspecified
Z71.9 [45561648]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1435
—
—
—
—
—
—
loperamide; oral
A07DA03 [21600646]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
7
134
1329
Tacrine, donepezil, rivastigmine, galantamine and other major and expensive drugs used to treat Alzheimer's disease
307 [2001600266]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
134
1331
Eye discharge
F03 [2002000401]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
134
1331
Extractable nuclear Ab [Units/volume] in Serum
30342-0 [3015171]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
7
134
1329
Pathology report gross observation
24419-4 [3002256]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
0
11
134
1325
Headache
R51.80 [2000503603]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.73%
controls:1.27%
—
—
—
—
—
—
5
17
129
1319
Basic examination of mouth
SAA02 [2001310275]
3.0e-01
—
—
—
—
1.6e-01
-7.3e-02
cases:11.56%
controls:8.81%
—
—
—
—
—
—
—
—
cases:4.83%
controls:4.16%
cases:11.94%
controls:12.72%
17
127
130
1315
—
—
—
—
7
59
138
1360
16
170
118
1166
Emergency visit or other similar visit involving procedures
WYA05 [2001310871]
2.4e-01
—
—
—
—
—
2.8e-01
cases:6.80%
controls:5.41%
—
—
—
—
—
—
—
—
—
—
cases:5.97%
controls:4.57%
10
78
137
1364
—
—
—
—
—
8
61
126
1275
lithium; oral
N05AN01 [21604556]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
134
1331
General Surgery
2 [38004447]
1.7e-01
9.2e-01
—
—
—
6.1e-01
1.7e-01
cases:19.05%
controls:16.57%
cases:9.52%
controls:4.02%
—
—
—
—
—
—
cases:8.28%
controls:4.65%
cases:17.16%
controls:14.90%
28
239
119
1203
14
58
133
1384
—
—
—
12
66
133
1353
23
199
111
1137
formoterol, glycopyrronium bromide and budesonide
R03AL11 [715850]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.69%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
0
10
147
1432
0
5
147
1437
—
—
—
0
5
145
1414
—
amitriptyline; oral, parenteral
N06AA09 [21604696]
3.5e-01
—
—
—
-1.0e+50
-1.0e+50
—
cases:3.40%
controls:2.43%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:1.55%
—
—
5
35
142
1407
—
—
—
0
5
147
1437
0
22
145
1397
—
Insertion of intrauterine device
TLC00 [2001306647]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
0
9
147
1433
—
—
—
—
—
0
6
134
1330
Chest pain, unspecified
R07.4 [45558450]
1.0e+00
-1.0e+50
—
—
—
—
—
cases:4.76%
controls:1.73%
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
7
25
140
1417
0
9
147
1433
—
—
—
—
—
Derangement of meniscus due to old tear or injury
M23.2 [45591779]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1436
—
—
—
—
—
—
Physical Medicine And Rehabilitation
25 [38004468]
7.0e-01
1.1e+00
—
—
—
—
1.1e+00
cases:5.44%
controls:2.77%
cases:4.08%
controls:1.46%
—
—
—
—
—
—
—
—
cases:8.96%
controls:3.22%
8
40
139
1402
6
21
141
1421
—
—
—
—
12
43
122
1293
Sprain and strain of other and unspecified parts of knee
S83.6 [45579536]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1436
—
—
—
—
—
—
bupropion; oral
N06AX12 [21604741]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.42%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.82%
0
8
147
1434
0
6
147
1436
—
—
—
0
5
145
1414
0
11
134
1325
Missed abortion
O02.1 [45567878]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
0
10
147
1432
—
—
—
—
—
0
9
134
1327
Nutrition survey
SPAT1139 [2001700240]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
Open wound of finger(s) without damage to nail
S61.0 [45578756]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1435
—
—
—
—
—
—
Car occupant [any] injured in unspecified traffic accident
V49.9 [45566025]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1435
—
—
—
—
—
—
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
6.9e-01
—
—
—
—
—
—
cases:3.40%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
—
—
5
25
142
1417
—
—
—
—
—
—
timolol
S01ED01 [21603699]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
0
6
147
1436
—
—
lactulose; oral
A06AD11 [21600571]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1436
—
—
—
—
—
Knee symptom/complaint
L15 [2002000639]
—
-1.0e+50
—
—
—
—
7.5e-01
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
cases:4.48%
controls:2.17%
—
0
9
147
1433
—
—
—
—
6
29
128
1307
Memory test
SPAT1053 [2001700154]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1436
—
—
—
—
—
Amphetamines [Presence] in Urine
3349-8 [3027944]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
16
134
1320
Sensorineural hearing loss, bilateral
H90.3 [45576850]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
0
8
145
1411
—
Other somatoform disorders
F45.8 [45600750]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
Ulcer of lower limb, not elsewhere classified
L97 [45591659]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
134
1331
Toxoplasma oculopathy
B58.0 [45571475]
—
—
—
1.0e+50
1.0e+50
1.0e+50
—
—
—
—
—
—
—
cases:12.24%
controls:0.00%
cases:8.84%
controls:0.00%
cases:5.52%
controls:0.00%
—
—
—
—
—
18
0
129
1442
13
0
134
1442
8
0
137
1419
—
Hypertrophy of breast
N62 [45577538]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
134
1331
Orthopedic Surgery
20 [38004465]
2.2e-02
4.4e-01
-1.0e+50
—
—
—
6.0e-01
cases:8.84%
controls:8.67%
cases:4.76%
controls:3.12%
cases:0.00%
controls:0.49%
—
—
—
—
—
—
cases:17.91%
controls:10.70%
13
125
134
1317
7
45
140
1397
0
7
147
1435
—
—
—
24
143
110
1193
Pregnancy symptom/complaint other
W29 [2002001222]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1436
—
—
—
—
—
—
aripiprazole; oral, parenteral
N05AX12 [21604562]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
0
12
147
1430
—
—
—
—
0
6
145
1413
—
Streptococcal tonsillitis
J03.0 [45601114]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
lymecycline; oral, parenteral
J01AA04 [21602802]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
7
145
1412
—
Nonorganic sleep disorders
F51 [45552491]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
Neurosurgery
14 [38004459]
9.7e-01
—
—
—
—
-1.0e+50
8.9e-01
cases:3.40%
controls:1.32%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:3.73%
controls:1.57%
5
19
142
1423
—
—
—
—
0
5
145
1414
5
21
129
1315
Psychiatric treatment plan, standard
ICB01 [2001304098]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
134
1331
insulin lispro; parenteral
A10AC04 [21600726]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
0
10
147
1432
—
—
Accelerated psychiatric treatment contact
IGY01 [2001304321]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
6
134
1330
oxcarbazepine; oral
N03AF02 [21604418]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.42%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
0
6
147
1436
0
5
147
1437
—
—
—
0
5
145
1414
—
metronidazole
D06BX01 [21602096]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
Acute appendicitis, unspecified
K35.9 [45557651]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
9
147
1433
—
—
—
—
—
0
7
134
1329
Cytomegalovirus IgG Ab [Titer] in Serum or Plasma
22246-3 [3017918]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
7
134
1329
Gestational [pregnancy-induced] hypertension
O13 [45539091]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
Health check-up performed during second study year in students of upper secondary schools, vocational schools etc.
SPAT1364 [2001700465]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
Spinal stenosis
M48.0 [45557888]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
0
6
145
1413
—
Delivery without mention of complication, Occipital presentation
65000 [2000303663]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1435
—
—
—
—
—
—
Psychosocial counselling and guidance
SPAT1307 [2001700408]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
0
6
147
1436
—
—
—
—
0
6
145
1413
—
Gastroenterology
10 [38004455]
4.8e-01
—
—
—
—
—
5.3e-01
cases:4.08%
controls:2.57%
—
—
—
—
—
—
—
—
—
—
cases:4.48%
controls:2.69%
6
37
141
1405
—
—
—
—
—
6
36
128
1300
FEV1
20150-9 [3024653]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1436
—
—
—
—
—
—
hydrocortisone and antiinfectives
S01CA03 [21603654]
1.5e+00
-1.0e+50
—
—
—
—
—
cases:4.08%
controls:0.97%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
6
14
141
1428
0
5
147
1437
—
—
—
—
—
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
-1.0e+50
—
—
—
—
—
1.4e+00
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
cases:3.73%
controls:0.97%
0
15
147
1427
—
—
—
—
—
5
13
129
1323
Psychological disorders other
P99 [2002000880]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
0
7
147
1435
—
—
—
—
—
0
6
134
1330
Diabetes mellitus without mention of complication[DIABETES MELLITUS SINE COMPLICATIONE ,TYYPPI I]
2500B [2000402295]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
147
1430
—
—
—
—
—
—
Polycystic ovarian syndrome
E28.2 [45533028]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
6
134
1330
Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum
31374-2 [3007080]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
6
134
1330
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.67%
—
—
—
—
—
0
5
145
1414
0
9
134
1327
saccharomyces boulardii; oral
A07FA02 [21600670]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
7
134
1329
Insect bite/sting
S12 [2002000977]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
147
1434
—
—
—
—
—
—
tamsulosin; oral
G04CA02 [21602669]
6.9e-01
—
—
—
—
1.1e+00
4.3e-01
cases:3.40%
controls:1.73%
—
—
—
—
—
—
—
—
cases:3.45%
controls:1.13%
cases:3.73%
controls:2.47%
5
25
142
1417
—
—
—
—
5
16
140
1403
5
33
129
1303
enoxaparin; parenteral
B01AB05 [21600976]
—
—
—
—
—
—
5.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.48%
controls:2.62%
—
—
—
—
—
—
6
35
128
1301
vilanterol and fluticasone furoate
R03AK10 [43534841]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
0
5
147
1437
—
—
—
—
0
5
134
1331
hepatitis A, inactivated, whole virus
J07BC02 [21601339]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
6
134
1330
Carboxyhemoglobin/Hemoglobin.total in Blood
20563-3 [3023081]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.52%
0
5
147
1437
—
—
—
—
0
5
145
1414
0
7
134
1329
rivaroxaban; oral
B01AF01 [43534761]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
Obesity due to excess calories
E66.01 [2000501501]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1435
—
—
—
—
—
Hyperglycaemia, unspecified
R73.9 [45602038]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
6
134
1330
Back syndrome with radiating pain
L86 [2002000705]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
134
1331
metronidazole; vaginal
G01AF01 [21602392]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1435
—
—
—
—
—
Fracture of lateral malleolus
S82.6 [45569819]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
134
1331
Hemoglobin [Mass/volume] in Venous blood
30350-3 [3004119]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
10
134
1326
Restricted health certificate
SPAT1283 [2001700384]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
0
8
147
1434
—
—
—
0
8
145
1411
—
telmisartan and diuretics
C09DA07 [21601839]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
7
147
1435
0
5
147
1437
—
—
—
—
0
7
134
1329
ramipril; oral
C09AA05 [21601789]
7.8e-01
—
—
—
—
—
5.8e-01
cases:5.44%
controls:2.57%
—
—
—
—
—
—
—
—
—
—
cases:5.97%
controls:3.44%
8
37
139
1405
—
—
—
—
—
8
46
126
1290
Student oral health check consistent with decree to assess need for oral health guidance and services
WYA50 [2001310877]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.42%
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
0
6
147
1436
0
7
147
1435
—
—
—
—
0
13
134
1323
Cytology report of Cervical or vaginal smear or scraping Cyto stain
47528-5 [3050380]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
0
7
147
1435
0
5
147
1437
—
—
—
—
0
11
134
1325
Migraine
N89 [2002000789]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
6
134
1330
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
Other hammer toe(s) (acquired)
M20.4 [45562664]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
hydrocortisone buteprate
D07AB11 [21602115]
5.1e-01
—
-1.0e+50
—
—
—
2.9e-01
cases:9.52%
controls:5.96%
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:7.46%
controls:5.69%
14
86
133
1356
—
0
5
147
1437
—
—
—
10
76
124
1260
Migraine
G43 [45566873]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
0
14
134
1322
Caries limited to enamel
K02.0 [45576967]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
—
0
10
147
1432
—
—
—
—
—
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
0
17
134
1319
Glucose [Moles/volume] in Serum or Plasma --2 hours post meal
14761-1 [3012413]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
134
1331
antibiotics in combination with corticosteroids
D01AA20 [21601918]
1.4e+00
—
—
—
—
—
—
cases:4.76%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
—
—
7
18
140
1424
—
—
—
—
—
—
Pulmonary Disease
29 [38004472]
-3.5e-02
8.4e-01
—
—
—
9.6e-01
9.6e-01
cases:4.76%
controls:4.92%
cases:5.44%
controls:2.43%
—
—
—
—
—
—
cases:5.52%
controls:2.18%
cases:11.94%
controls:4.94%
7
71
140
1371
8
35
139
1407
—
—
—
8
31
137
1388
16
66
118
1270
Examination and observation for other specified reasons
Z04.8 [45552063]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
147
1433
—
—
—
—
—
—
Coxarthrosis, unspecified
M16.9 [45591742]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
7
134
1329
Aortic (valve) insufficiency
I35.1 [45572087]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
venlafaxine; oral
N06AX16 [21604745]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
0
6
147
1436
—
0
5
147
1437
—
—
Photography of fundus of the eye or interpretation of photograph
SPAT1008 [2001700109]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
ethylmorphine; oral
R05DA01 [21603397]
6.1e-01
—
—
—
—
—
1.1e+00
cases:3.40%
controls:1.87%
—
—
—
—
—
—
—
—
—
—
cases:4.48%
controls:1.50%
5
27
142
1415
—
—
—
—
—
6
20
128
1316
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
0
18
134
1318
Other specified urinary incontinence
N39.4 [45577525]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1435
—
—
—
—
—
—
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
5.2e-01
—
—
—
—
—
2.5e-01
cases:6.12%
controls:3.74%
—
—
—
—
—
—
—
—
—
—
cases:3.73%
controls:2.92%
9
54
138
1388
—
—
—
—
—
5
39
129
1297
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
3.6e-01
—
—
—
—
—
5.3e-01
cases:7.48%
controls:5.34%
—
—
—
—
—
—
—
—
—
—
cases:5.22%
controls:3.14%
11
77
136
1365
—
—
—
—
—
7
42
127
1294
ispaghula (psylla seeds); oral
A06AC01 [21600555]
—
—
—
—
—
—
4.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.73%
controls:2.47%
—
—
—
—
—
—
5
33
129
1303
Health check-up performed during first study year in students of upper secondary schools, vocational schools etc.
SPAT1363 [2001700464]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
134
1331
Paraesthesia of skin
R20.2 [45568120]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
147
1431
—
—
—
—
—
—
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
5.4e-01
8.2e-01
—
—
—
—
5.0e-01
cases:4.08%
controls:2.43%
cases:3.40%
controls:1.53%
—
—
—
—
—
—
—
—
cases:5.22%
controls:3.22%
6
35
141
1407
5
22
142
1420
—
—
—
—
7
43
127
1293
fusidic acid
D09AA02 [21602265]
6.5e-01
-1.0e+50
—
—
—
—
—
cases:3.40%
controls:1.80%
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
5
26
142
1416
0
9
147
1433
—
—
—
—
—
insulin aspart; parenteral
A10AB05 [21600719]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
147
1437
—
0
9
147
1433
—
—
Profession-specific psychiatric evaluation
IBZ01 [2001304075]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
6
134
1330
Gynaecological examination (general)(routine)
Z01.4 [45542395]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
0
5
145
1414
—
nizatidine; oral, parenteral
A02BA04 [21600085]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1435
—
—
—
—
—
—
empagliflozin; oral
A10BK03 [1123740]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.69%
cases:0.00%
controls:0.35%
—
—
—
—
cases:0.00%
controls:0.63%
cases:0.00%
controls:1.12%
0
7
147
1435
0
10
147
1432
0
5
147
1437
—
—
0
9
145
1410
0
15
134
1321
Oxygen saturation in Arterial blood
2708-6 [3016502]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
16
134
1320
Laparoscopic appendectomy
JEA01 [2001304803]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1437
—
—
—
—
—
—
chorionic gonadotrophin; parenteral
G03GA01 [21602599]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.90%
—
—
—
—
—
0
5
145
1414
0
12
134
1324
salbutamol; inhalant
R03AC02 [21603256]
-3.6e-01
1.8e-01
-1.0e+50
—
-1.0e+50
5.8e-01
2.5e-01
cases:5.44%
controls:7.63%
cases:4.76%
controls:4.02%
cases:0.00%
controls:0.76%
—
—
cases:0.00%
controls:0.55%
cases:5.52%
controls:3.17%
cases:13.43%
controls:10.78%
8
110
139
1332
7
58
140
1384
0
11
147
1431
—
0
8
147
1434
8
45
137
1374
18
144
116
1192
latanoprost
S01EE01 [21603710]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.73%
controls:0.75%
—
—
—
—
—
—
5
10
129
1326
Geriatric Medicine
38 [38004478]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.42%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
0
6
147
1436
0
5
147
1437
—
—
—
—
—
enalapril and diuretics
C09BA02 [21601804]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
cases:0.00%
controls:0.82%
—
—
—
—
—
0
9
145
1410
0
11
134
1325
citalopram; oral, parenteral
N06AB04 [21604712]
6.0e-01
8.0e-01
—
—
—
7.7e-01
1.1e-01
cases:5.44%
controls:3.05%
cases:4.08%
controls:1.87%
—
—
—
—
—
—
cases:3.45%
controls:1.62%
cases:4.48%
controls:4.04%
8
44
139
1398
6
27
141
1415
—
—
—
5
23
140
1396
6
54
128
1282
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
0
8
147
1434
—
—
—
—
—
carvedilol; oral
C07AG02 [21601700]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
147
1431
—
—
—
—
—
—
tamsulosin and dutasteride
G04CA52 [21602673]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
0
6
147
1436
—
—
—
0
7
145
1412
—
gabapentin; oral
N02BF01 [955005]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
0
9
145
1410
—
Epstein Barr virus Ab [Presence] in Serum
49178-7 [3048929]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
8
134
1328
One hour or less
ZXE00 [2001311394]
-1.8e-01
1.0e+00
—
—
—
1.4e+00
8.4e-01
cases:4.08%
controls:4.85%
cases:4.08%
controls:1.53%
—
—
—
—
—
—
cases:4.14%
controls:1.06%
cases:7.46%
controls:3.37%
6
70
141
1372
6
22
141
1420
—
—
—
6
15
139
1404
10
45
124
1291
Diabetes mellitus in pregnancy, unspecified
O24.9 [45539107]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1435
—
—
—
—
—
—
doxycycline; oral, parenteral
J01AA02 [21602800]
2.4e-01
4.1e-01
—
—
—
2.1e-01
2.1e-01
cases:19.73%
controls:16.23%
cases:5.44%
controls:3.68%
—
—
—
—
—
—
cases:4.83%
controls:3.95%
cases:16.42%
controls:13.70%
29
234
118
1208
8
53
139
1389
—
—
—
7
56
138
1363
22
183
112
1153
furosemide; oral, parenteral
C03CA01 [21601518]
—
5.4e-01
-1.0e+50
—
—
5.3e-01
6.3e-01
—
—
cases:4.08%
controls:2.43%
cases:0.00%
controls:0.83%
—
—
—
—
cases:4.14%
controls:2.47%
cases:7.46%
controls:4.12%
—
6
35
141
1407
0
12
147
1430
—
—
6
35
139
1384
10
55
124
1281
phenoxymethylpenicillin; oral
J01CE02 [21602842]
4.3e-01
—
—
—
-1.0e+50
—
5.7e-01
cases:17.01%
controls:11.72%
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
cases:18.66%
controls:11.45%
25
169
122
1273
—
—
—
0
6
147
1436
—
25
153
109
1183
metformin and sitagliptin
A10BD07 [21600772]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.42%
cases:0.00%
controls:0.42%
—
—
—
—
cases:0.00%
controls:0.42%
cases:0.00%
controls:0.45%
0
7
147
1435
0
6
147
1436
0
6
147
1436
—
—
0
6
145
1413
0
6
134
1330
chondroitin sulfate
M01AX25 [21604013]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
cases:0.00%
controls:0.90%
0
9
147
1433
—
—
—
—
0
8
145
1411
0
12
134
1324
fluticasone; nasal
R01AD08 [21605050]
-1.7e-01
—
-1.0e+50
—
—
—
2.0e-01
cases:5.44%
controls:6.38%
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
cases:8.21%
controls:6.81%
8
92
139
1350
—
0
6
147
1436
—
—
—
11
91
123
1245
Open wound of scalp
S01.0 [45592468]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
9
134
1327
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1435
—
—
—
—
—
—
Coloscopy
UJF32 [2001305029]
4.4e-01
—
—
—
—
—
—
cases:3.40%
controls:2.22%
—
—
—
—
—
—
—
—
—
—
—
—
5
32
142
1410
—
—
—
—
—
—
Acute suppurative otitis media
H66.0 [45572040]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
0
12
134
1324
Buprenorphine [Presence] in Urine by Screen method
93494-3 [1001926]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
0
11
134
1325
Constipation, unspecified
K59.09 [2000502926]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
134
1331
boric acid
S02AA03 [21605149]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
5
147
1437
—
—
—
—
—
0
7
134
1329
Wrist symptom/complaint
L11 [2002000635]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
0
5
147
1437
—
—
—
—
—
0
8
134
1328
Outcome of delivery
Z37 [45581024]
-4.0e-01
—
—
—
—
9.3e-01
1.9e-01
cases:6.12%
controls:8.88%
—
—
—
—
—
—
—
—
cases:6.21%
controls:2.54%
cases:8.21%
controls:6.89%
9
128
138
1314
—
—
—
—
9
36
136
1383
11
92
123
1244
Ventricular premature depolarization
I49.3 [45538386]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
147
1434
—
—
—
—
—
—
brinzolamide, combinations
S01EC54 [45893490]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1436
—
—
—
—
—
choriogonadotropin alfa; parenteral
G03GA08 [21602606]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.90%
—
—
—
—
—
0
5
145
1414
0
12
134
1324

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
23
20
12.73
13.17
2.9
3.1
61.59
—
iu/ml
—
10
0
63
295
2.61
8.65
1.2
1.4
360.00
510.12
titre
0.60
15
81
10
9
11.58
5.85
3.5
1.2
1064.20
879.00
u/ml
—
10
9
94
631
1.87
4.73
11.0
5.7
—
—
—
0
0
143
1098
1.90
4.67
12.7
9.9
4.02
4.09
e9/l
0.13
124
961
11
18
6.38
4.66
1.2
1.2
—
—
—
0
0
133
1003
1.85
4.54
9.0
6.2
1.88
1.82
e9/l
0.38
117
881
130
985
1.81
4.26
9.1
6.2
0.57
0.57
e9/l
0.01
111
841
130
989
1.80
4.16
9.1
6.2
0.04
0.04
e9/l
0.44
111
842
122
917
1.76
4.01
9.4
6.2
29.27
28.05
%
0.64
115
872
14
43
3.41
3.98
1.2
1.4
—
—
—
0
0
11
23
4.98
3.93
1.2
1.3
—
—
—
0
0
132
1020
1.76
3.89
10.5
6.4
0.19
0.19
e9/l
0.09
115
885
119
895
1.74
3.85
9.9
6.2
0.77
0.70
%
0.53
111
833
119
900
1.72
3.73
9.8
6.2
2.70
2.80
%
0.20
112
845
13
36
3.78
3.56
1.5
1.3
277.80
243.82
u/ml
—
5
17
14
47
3.12
3.48
1.3
1.1
—
—
—
0
0
118
903
1.68
3.44
10.0
6.2
8.85
8.68
%
0.31
111
851
21
90
2.48
3.37
2.7
1.8
5.88
4.37
iu/ml
—
9
20
72
491
1.70
3.19
2.6
2.7
354.72
333.84
umol/l
0.92
65
437
86
617
1.66
3.14
3.9
3.3
25.05
146.28
e6/l
0.60
61
473
16
65
2.58
2.86
1.5
1.4
—
—
—
0
0
49
309
1.76
2.84
3.5
2.3
12.88
13.69
umol/l
0.32
43
289
64
435
1.67
2.83
3.4
2.6
6.57
5.65
e6/l
0.13
57
401
46
285
1.78
2.83
3.7
2.3
2.35
2.36
g/l
0.05
40
263
75
535
1.62
2.73
3.9
3.0
0.39
0.37
e6/l
0.04
52
395
5
7
7.28
2.56
1.0
1.0
—
—
—
0
0
67
475
1.60
2.47
7.7
4.2
—
—
—
0
0
80
595
1.55
2.39
6.9
4.1
7.40
7.40
ph
0.09
55
416
26
142
1.95
2.36
3.0
2.5
35.84
19.18
au/ml
—
5
15
94
729
1.51
2.30
4.8
3.9
72.36
62.27
e6/l
0.10
66
501
15
67
2.33
2.23
4.3
4.0
121.78
267.33
mg/l
—
9
24
31
185
1.79
2.16
5.3
3.3
1.72
1.91
%
0.65
24
172
41
267
1.66
2.10
3.9
2.4
20.71
23.02
%
0.50
36
251
8
26
3.15
2.03
1.3
1.2
—
—
—
0
0
55
389
1.56
2.02
1.8
2.1
—
—
—
0
0
41
272
1.63
1.96
1.3
2.2
53.10
99.57
ug/g
1.36
35
221
166
1475
1.55
1.95
10.4
7.8
83.43
78.33
u/l
0.60
160
1392
80
617
1.47
1.94
2.7
2.2
—
—
—
0
0
36
232
1.66
1.92
1.7
1.9
—
—
—
0
0
8
28
2.93
1.88
1.4
1.4
—
—
—
0
0
78
604
1.46
1.84
9.9
6.6
—
—
—
0
0
61
450
1.50
1.83
4.8
3.7
—
0.00
—
0
5
5
12
4.24
1.83
1.0
1.0
—
—
—
0
0
25
148
1.78
1.80
1.0
1.2
204.38
104.25
u/ml
—
9
57
103
844
1.42
1.78
4.1
3.4
6.12
6.19
ph
0.21
53
481
9
36
2.56
1.76
1.0
1.1
—
—
—
0
0
26
157
1.75
1.75
2.0
1.5
—
—
—
0
0
13
61
2.20
1.75
2.1
1.7
113.00
305.99
ug/l
1.71
13
55
21
119
1.85
1.73
1.6
2.5
—
—
—
0
0
0
46
0.00
1.73
0.0
5.0
—
24.11
—
0
32
36
242
1.59
1.64
2.9
2.5
11.07
7.44
umol/l
0.29
30
214
5
14
3.63
1.62
12.4
5.2
1897.80
919.36
mg
—
5
14
109
913
1.39
1.61
9.8
7.0
1.21
1.22
mmol/l
0.52
91
790
8
32
2.56
1.61
1.0
1.0
—
—
—
0
0
7
27
2.64
1.53
1.0
1.2
—
—
—
0
0
101
842
1.38
1.51
8.3
6.2
1.21
1.22
mmol/l
1.04
91
781
18
102
1.83
1.50
6.4
3.8
22.93
24.53
mmol/l
2.69
18
102
22
135
1.70
1.42
3.9
3.2
63.54
75.05
e9/l
0.85
17
97
58
447
1.41
1.37
5.5
3.9
1.02
1.02
kg/l
0.13
37
296
206
1978
1.99
1.36
25.9
18.7
77.68
74.47
umol/l
0.70
206
1951
28
186
1.58
1.35
6.6
8.7
7.42
7.41
ph
0.46
16
112
38
271
1.49
1.34
2.9
1.9
—
—
—
0
0
28
187
1.57
1.32
6.2
8.7
0.14
0.90
mmol/l
0.59
20
154
57
442
1.39
1.29
2.0
1.8
0.95
1.23
mg/l
0.54
44
358
121
1062
1.32
1.19
4.8
3.8
0.00
0.01
estimate
0.50
21
212
6
26
2.34
1.19
1.5
1.3
—
—
—
0
0
6
26
2.34
1.19
1.5
1.3
—
—
—
0
0
6
26
2.34
1.19
1.5
1.3
—
—
—
0
0
6
26
2.34
1.19
1.5
1.3
—
—
—
0
0
120
1054
1.31
1.17
4.9
3.7
0.00
7.12
estimate
0.50
21
228
5
20
2.53
1.15
1.2
1.1
269.40
261.53
mosm/kgh2o
—
5
15
53
415
1.37
1.13
1.3
1.3
21.68
24.65
iu/ml
0.14
13
128
14
81
1.78
1.12
1.0
1.1
—
—
—
0
0
198
1888
1.62
1.09
21.5
14.5
23.50
21.38
mg/l
0.32
161
1527
34
248
1.44
1.08
2.4
1.6
—
—
—
0
0
118
1045
1.29
1.04
4.8
3.7
0.00
0.00
estimate
-0.00
21
221
6
28
2.17
0.92
1.2
1.1
—
—
—
0
0
6
28
2.17
0.92
1.3
1.4
—
—
—
0
0
89
770
1.27
0.92
2.3
2.0
—
—
—
0
0
95
829
1.26
0.91
6.5
4.7
35.22
36.24
g/l
0.89
88
789
8
43
1.89
0.88
3.4
2.4
54.88
61.56
%
—
8
43
24
171
1.45
0.88
6.7
3.9
7.36
7.39
ph
1.27
17
98
6
30
2.03
0.87
4.0
2.3
3.48
5.17
e9/l
—
6
30
91
793
1.26
0.87
4.8
3.6
0.00
0.02
estimate
0.74
18
188
58
479
1.29
0.86
2.7
2.0
2.52
2.78
mg/l
0.59
50
415
8
45
1.81
0.85
8.0
3.5
7.42
7.41
ph
—
8
45
61
509
1.28
0.83
1.2
1.3
2.26
1.20
u/ml
0.34
11
149
189
1804
1.39
0.82
5.2
5.0
5.85
5.88
mmol/l
0.15
177
1687
6
32
1.90
0.82
7.3
2.9
9.23
8.73
kpa
—
6
32
6
32
1.90
0.82
7.3
2.9
4.65
4.98
kpa
—
6
32
8
47
1.73
0.81
3.9
2.4
58.58
58.59
%
—
8
47
6
34
1.79
0.77
7.7
2.5
—
—
—
0
0
44
356
1.30
0.76
4.3
3.3
224.29
284.83
ng/l
0.12
35
273
185
1765
1.35
0.76
5.9
5.6
1.90
1.86
mu/l
0.18
174
1642
42
338
1.30
0.76
1.9
1.7
—
—
—
0
0
67
572
1.25
0.76
3.9
3.0
—
—
—
0
0
5
24
2.11
0.75
1.6
1.7
33.00
32.42
pg
—
5
24
5
24
2.11
0.75
1.2
1.1
—
—
—
0
0
6
110
0.53
0.74
1.3
1.2
—
—
—
0
0
75
650
1.24
0.74
3.9
3.1
7.73
7.87
mmol/l
0.09
64
560
55
460
1.26
0.74
1.6
1.4
2.23
2.47
g/l
0.31
35
279
24
178
1.39
0.72
1.2
1.2
—
—
—
0
0
195
1878
1.41
0.72
5.2
5.1
4.61
4.71
mmol/l
0.56
183
1768
5
26
1.94
0.71
2.2
1.9
—
—
—
0
0
22
162
1.40
0.69
4.3
3.2
—
—
—
0
0
5
27
1.87
0.69
1.0
1.5
0.18
0.16
nmol/l
—
5
19
73
827
0.82
0.66
3.1
3.0
—
—
—
0
0
7
44
1.61
0.66
3.1
2.2
8.93
8.36
kpa
—
7
44
5
29
1.74
0.64
1.0
1.1
—
—
—
0
0
16
221
0.70
0.64
1.0
1.3
—
—
—
0
0
196
1898
1.37
0.60
5.7
5.7
2.68
2.76
mmol/l
0.65
182
1783
35
284
1.28
0.60
3.6
3.0
1.77
2.33
e6/l
0.32
13
130
74
653
1.20
0.60
3.4
3.4
2.37
2.36
mmol/l
0.13
66
596
13
89
1.49
0.59
3.5
4.4
—
—
—
0
0
79
704
1.19
0.58
3.7
3.6
23.45
26.39
ng/l
0.27
47
466
185
1782
1.27
0.56
4.5
4.2
1.31
1.29
mmol/l
0.08
169
1654
33
269
1.27
0.55
1.2
1.3
—
—
—
0
0
159
1511
1.20
0.53
4.8
4.6
14.67
14.76
pmol/l
0.17
148
1396
193
1871
1.31
0.53
5.1
5.0
1.47
1.48
mmol/l
0.11
178
1753
19
144
1.35
0.53
9.2
10.0
—
—
—
0
0
9
65
1.40
0.51
1.6
1.3
—
—
—
0
0
7
50
1.41
0.45
6.0
9.9
—
—
—
0
0
104
965
1.15
0.44
3.8
3.0
125.16
102.34
ug/l
0.69
95
913
97
896
1.15
0.44
19.4
10.8
0.00
0.00
e9/l
0.93
76
731
62
555
1.16
0.42
1.8
1.6
15.92
21.81
nmol/l
3.76
55
469
78
851
0.87
0.42
2.1
1.9
1.37
1.39
mmol/l
0.08
67
727
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
279.10
—
0
10
16
124
1.31
0.40
1.4
1.2
—
—
—
0
0
44
385
1.18
0.39
1.3
1.3
7.52
9.06
u/ml
0.11
19
151
5
35
1.44
0.39
8.6
3.1
9.10
8.70
pmol/l
—
5
35
16
125
1.30
0.38
4.9
3.4
—
—
—
0
0
6
45
1.34
0.34
2.8
2.1
21.15
24.88
mmol/l
—
6
45
199
1952
1.26
0.34
18.0
12.7
—
—
—
0
0
95
889
1.12
0.33
3.4
2.7
—
—
estimate
—
0
0
30
258
1.19
0.33
1.6
1.6
—
—
—
0
0
7
57
1.24
0.29
1.1
1.2
—
—
—
0
0
12
94
1.29
0.28
1.1
1.2
—
—
—
0
0
12
95
1.28
0.27
2.4
2.3
—
—
—
0
0
6
81
0.73
0.24
1.2
1.1
0.74
0.89
g/l
—
6
81
5
39
1.29
0.23
1.0
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
141.94
—
0
10
63
591
1.09
0.20
3.7
3.2
108.83
53.14
mg/l
0.78
41
378
6
49
1.23
0.20
1.2
1.2
—
—
—
0
0
7
59
1.19
0.18
1.4
1.2
—
—
—
0
0
22
196
1.14
0.17
1.5
4.4
2.13
31.01
ug/l
0.75
15
164
6
78
0.76
0.16
1.2
1.1
1.43
1.53
g/l
—
6
78
27
247
1.11
0.14
1.3
1.2
—
—
—
0
0
19
170
1.13
0.14
1.7
1.3
—
—
—
0
0
63
601
1.07
0.13
4.0
3.1
0.05
0.01
estimate
0.35
19
186
87
839
1.06
0.13
18.6
11.1
1.22
1.18
inr
0.34
72
679
24
219
1.11
0.13
2.2
1.6
—
—
—
0
0
85
822
1.06
0.12
2.4
2.1
105.43
96.77
pmol/l
0.81
45
426
39
368
1.07
0.11
2.6
2.6
2.42
2.45
mmol/l
1.04
33
335
10
115
0.86
0.11
1.3
1.8
—
—
—
0
0
5
65
0.76
0.08
2.4
2.2
—
—
—
0
0
11
98
1.13
0.08
3.2
1.4
—
—
—
0
0
59
571
1.05
0.07
5.5
3.8
0.00
0.00
estimate
-0.00
17
210
135
1370
0.96
0.07
4.1
3.3
58.21
44.69
u/l
0.65
130
1305
48
463
1.05
0.07
6.0
4.6
—
—
—
0
0
64
623
1.04
0.06
2.6
2.4
56.36
63.49
u/l
0.46
55
582
17
160
1.07
0.04
3.8
2.5
6.33
6.18
ph
—
9
105
62
607
1.03
0.04
4.3
3.9
24.83
8.91
mg/mmol
0.79
38
371
11
101
1.09
0.04
3.4
1.4
—
—
—
0
0
11
101
1.09
0.04
2.5
1.4
—
—
—
0
0
11
101
1.09
0.04
3.5
1.4
—
—
—
0
0
58
570
1.02
0.02
1.6
1.5
—
—
—
0
0
12
113
1.07
0.02
2.7
2.9
7.41
7.43
ph
0.53
12
90
25
243
1.03
0.01
7.3
7.4
105.00
104.14
mmol/l
0.81
25
243
10
94
1.07
0.01
1.8
1.8
—
—
—
0
0
11
109
1.01
0.00
1.0
1.1
—
—
—
0
0
25
246
1.02
0.00
1.4
1.4
—
—
—
0
0
28
284
0.98
0.00
2.4
2.9
0.44
0.77
ug/l
1.82
17
166
178
1776
1.01
0.00
5.8
6.1
38.32
38.99
mmol/mol
0.61
167
1688
29
285
1.02
0.00
2.3
1.7
1163.59
1193.15
nmol/l
0.07
20
218
0
5
0.00
0.00
0.0
1.4
—
1.67
—
0
5
0
5
0.00
0.00
0.0
2.2
—
3713.80
—
0
5
0
5
0.00
0.00
0.0
1.0
—
27.80
—
0
5
5
50
1.00
-0.00
3.8
1.5
—
—
—
0
0
8
82
0.97
-0.00
1.5
1.6
200.15
274.44
mu/l
—
8
77
8
83
0.96
-0.00
2.0
3.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
55
0.91
-0.00
2.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
5
54
0.92
-0.00
2.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
5.8
—
46.50
—
0
6
9
96
0.93
-0.00
3.7
1.4
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: AB1_TOXOPLASMOSIS_WIDE – Toxoplasmosis, including avohilmo

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).